Bio Protocol (BIO) has surged to a six-month high of $0.1514, rebounding from a low of $0.0962. This rise is driven by strategic biotech partnerships and increased staking activity. The token's trading volume soared by over 700% last week, reaching $440 million, reflecting strong investor interest. A significant factor in BIO's price increase is its involvement in a Phase 2 clinical trial for Percepta, a memory loss supplement, funded by Cerebrum DAO. Additionally, the staked BIO tokens have increased to 125 million, reducing liquid supply and potentially boosting price movements. Despite surpassing key resistance levels, traders remain cautious of potential short-term corrections.